Next Article in Journal
Plants and Natural Products with Activity against Various Types of Coronaviruses: A Review with Focus on SARS-CoV-2
Next Article in Special Issue
Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents
Previous Article in Journal
Photodegradation of Brilliant Green Dye by a Zinc bioMOF and Crystallographic Visualization of Resulting CO2
Previous Article in Special Issue
Bacterial Alkyl-4-quinolones: Discovery, Structural Diversity and Biological Properties
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 26
Issue 13
10.3390/molecules26134093
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis and Evaluation of Chalcone-Quinoline Based Molecular Hybrids as Potential Anti-Malarial Agents

by
Bonani Vinindwa
1,
Godwin Akpeko Dziwornu
2 and
Wayiza Masamba
1,*
1
Department of Chemical and Physical Sciences, Faculty of Natural Sciences, Walter Sisulu University, Nelson Mandela Drive, Mthatha 5117, South Africa
2
Department of Chemistry, University of Cape Town, Rondebosch 7700, South Africa
*
Author to whom correspondence should be addressed.
Molecules 2021, 26(13), 4093; https://doi.org/10.3390/molecules26134093
Submission received: 30 May 2021 / Revised: 27 June 2021 / Accepted: 1 July 2021 / Published: 5 July 2021
(This article belongs to the Special Issue Quinolones: Chemistry and Biological Activities)
Browse Figures
Versions Notes

Abstract

:
Molecular hybridization is a drug discovery strategy that involves the rational design of new chemical entities by the fusion (usually via a covalent linker) of two or more drugs, both active compounds and/or pharmacophoric units recognized and derived from known bioactive molecules. The expected outcome of this chemical modification is to produce a new hybrid compound with improved affinity and efficacy compared to the parent drugs. Additionally, this strategy can result in compounds presenting modified selectivity profiles, different and/or dual modes of action, reduced undesired side effects and ultimately lead to new therapies. In this study, molecular hybridization was used to generate new molecular hybrids which were tested against the chloroquine sensitive (NF54) strain of P. falciparum. To prepare the new molecular hybrids, the quinoline nucleus, one of the privileged scaffolds, was coupled with various chalcone derivatives via an appropriate linker to produce a total of twenty-two molecular hybrids in 11%–96% yield. The synthesized compounds displayed good antiplasmodial activity with IC50 values ranging at 0.10–4.45 μM.

Graphical Abstract

1. Introduction

Malaria is a life-threatening disease caused by the Plasmodium parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes [1]. Pregnant women, children under the age of 5 years, and people with weakened immune system are most likely to succumb to the morbidity and transience of the disease [2,3]. In 2019 the estimated malaria cases were 229 million with an approximated death toll of 409,000 [4]. Worldwide, children aged under 5 years, the most vulnerable group, accounted for 67% of the total malaria deaths in 2019. The World Health Organization (WHO) Africa region accounted for 82% of all cases and about 10% in the WHO South-East Asia region. P. falciparum is the most prevalent malaria parasite in the WHO regions of Africa, South-East Asia, the Eastern Mediterranean and the Western Pacific, accounting for 99.7% of all malaria cases in Africa, 50% in South-East Asia, 69% in Eastern Mediterranean, and 65% in Western Pacific. On the other hand, P. vivax is predominant in the WHO region of the Americas, representing 75% of malaria cases [5].
For a long time, chloroquine (CQ) remained the antimalarial drug of choice due to its high efficacy, low cost, and tolerable adverse effects. However, large scale use of CQ soon led to the emergence of CQ-resistant parasite strains [2]. Many other alternative drugs followed, including artemisinin combined therapies (ACTs), which for some time became one of the most effective, especially against P. falciparum, allowing millions of patients to be cured [1,2,3,6,7,8]. However, recent evidence of resistance to artemisinin reported in South Asia and along the Cambodia–Thailand border threatens this strategy [9]. Indeed, as soon as a new drug is introduced, it is just a matter of time before resistance appears. Under these circumstances, there is need to be one step ahead of the malaria parasite by designing new strategies in the fight against this pathology. Hence, multi-target hybrid drugs are needed as an alternative or compliment to existing therapies.
Molecular hybridization (MH) is a strategy of rational design of new ligands or prototypes based on the recognition of pharmacophoric subunits in the molecular structure of two or more known bioactive derivatives which through the adequate fusion of these subunits, leads to the formation of new hybrid architectures that maintain pre-selected characteristics of the original templates [8,10,11]. Hybrid drugs are designed to counterbalance the known side effects associated with the other hybrid part or to augment its effect through action on another biological target or to interact with multiple targets as one single molecule, lowering the risk of drug-drug interactions and surmount drug resistance [11]. Over the last few years, molecular hybridization has emerged as a novel approach that involves a combination of pharmacophoric elements which are so far known for different enzyme inhibition, leading to active compounds which show a balanced inhibition of enzyme and offers the opportunity to treat different diseases with better tolerated drugs, thus enhancing patient compliance [11]. We therefore sought to apply this concept of molecular hybridization in the design and synthesis of new hybrid compounds based on new hybrid compounds based on the quinoline and chalcone privileged scaffolds connected by an aminoalkylsulphonamide linker.
Privileged structures are core structural units known for binding to proteins, and which can be coupled to other active molecules to generate potential new drugs. 1,3-Diarylprop-2-en-1-ones or benzalacetophenones commonly known as chalcones belong to an important class of natural products widely distributed in the plant kingdom. They display an array of biological activities [12] such as antifungal [13], antiparasitic [14], antitumor and antioxidant [15], immunomodulatory [16] antileishmania [17], antimitotic [18], anti-invasive [19,20], anti-inflammatory [21,22] and antimalarial [23,24]. Licochalcone (Figure 1I), for example, is a natural compound isolated from Chinese liquorice roots, which has shown potent antiplasmodial activity [25]. Due to this broad range of biological activities, the chalcone molecule is one of the templates extensively used in molecular hybridization. When combined with quinolines, chalcones may be expected to exhibit high antiplasmodial activity.
Of the several antimalarial compounds described in literature, quinoline derivatives are still the dominant class [7]. Furthermore, the diverse pharmacological properties of the quinoline scaffold and derivatives attracted worldwide attention in the last few decades because of their wide occurrence in natural products, and drugs [26]. Synthetic hybrid compounds have been designed to increase the efficacy of quinoline derivatives because the antimalarial hybrid drugs have a lower risk of drug–drug adverse interactions and greater treatment adherence than the combined drugs. Some of the quinoline derivatives shown in Figure 1 have reached the stage of clinical trials. They include chalcone–chloroquinoline (II) [8], AZT–CQ (III) [27], quinine–dihydroartemisinin (IV) [28] and artesunate–mefloquine MEFAS (V) [7].
Quinoline–sulfonamide hybrid compounds such as those in Figure 2, which contain various linker groups connecting arylsulfonamide moieties to the aminoquinoline molecule, have been reported as potential antimalarial drugs [7,29,30,31,32,33]. Though most of them were less active when compared to chloroquine, they showed good antimalarial activity, acting by inhibiting parasite growth without interfering with the integrity of the red blood cell membrane [29].
Based on the above properties and literature precedents, we sought in this study to synthesize molecular hybrids comprising of a quinoline–sulfonamide and the relevant chalcones as potential antiplasmodial agents.

2. Results

2.1. Chemistry

The synthesis of molecular hybrids was carried out in three consecutive steps as outlined in Scheme 1. In a first step, the nucleophilic aromatic substitution reaction (SNAr) between 4,7-dichloroquinoline and the relevant diamines (n = 2 and 3) afforded the corresponding N-(7-chloroquinol-4-yl) alkyldiamines 2 and 3 in excellent yields (89% and 95%, respectively) [7,34], which were condensed with 4-acetylbenzenesulfonyl chloride in the presence of NaOH to afford 4-acetyl-N-(2-[(7-chloroquinolin-4-yl)amino]alkyl)benzenesulfonamides 4 and 5 in moderate yields (29 and 41%, respectively). Finally, a base-catalyzed Claisen-Schmidt coupling of these intermediates with various aryl aldehydes led to the expected molecular hybrids in 11%–96% yield. Table 1 summarizes the overall results in these reactions. Except for compounds 11, 12, 14, 18, 23, and 25, good to excellent yields were obtained in the condensation step. Only trans isomers of the chalcone moiety were obtained as confirmed by the coupling constant between the two olefinin protons (~15.65 Hz in all cases).

2.2. In-Vitro Antiplasmodial Activity Evaluation

All the synthesized molecular hybrids (6–27) were evaluated for in vitro antiplasmodial activity against the drug-sensitive strain (NF54) of P. falciparum and for cytotoxicity against the Chinese Hamster Ovary (CHO) mammalian cell line using emetine as a reference drug. Aqueous solubility was determined at pH 6.5 (Table 2).

3. Discussion

All synthesized compounds presented good activity with IC50 values ranging from 0.10 to 4.45 μM against the NF54 sensitive strain of P. falciparum.
Compared to the unsubstituted molecular hybrid 6 (IC50 = 1.67μM), fluoro-substituted derivatives 9, 15, and 24 are all more active (with IC50 (NF54) values of 0.28, 0.86, and 0.57 μM, respectively), suggesting the importance of electronic effects brought about by the more electronegative fluorine atom. The same trend can be noted with other halogens, such as bromine (compound 8; IC50 = 0.10 μM), chlorine (compound 11, IC50 = 0.10 μM), as well as a methoxy group (compound 12, IC50 = 0.11 μM). Compounds 8, 11, and 12 were the most active, displaying IC50 values of 0.10, 0.10, and 0.11 μM, respectively. These compounds were further tested against the multi-drug resistant K1 strain of P. falciparum. Compound 12 showed about two-fold improvement in resistivity index ((RI = 5.36), PfK1 IC50 = 0.59 μM) relative to CQ, making it the frontrunner compound in the present study. Meanwhile, compounds 8 and 11 were less active against the K1 strain with IC50 values of 2.97 μM and 6 μM, respectively.
In accordance with literature precedents [7], compounds with three methylene groups (n = 3) as linker showed greater activity against P. falciparum than those with two methylene groups (n = 2). Indeed, the introduction of an additional CH2 group (n = 3) in compound 12 enhances its potency approximately five-fold as compared to compound 17 (n = 2), while a two-fold increase is noticed going from compound 9 (n = 2, 0.28 μM) to compound 24 (n = 3, 0.57 μM). In addition, almost all molecular hybridscontaining three methylene groups as linker (7–12, 14–20) were amongst the most active of the series, with IC50 values ranging from 0.10–0.86 μM.
The less polar methyl group has very little effect on the activity as is observed in compounds 7 and 22 which both have a methyl group in para position and exhibited the same activity (IC50 = 0.37 μM and 0.39 μM, respectively).
Compounds 21 and 23, respectively, containing a 2-furanyl and ferrocenyl as the aromatic rings are among the less active, suggesting the importance of the chalcone unit in the overall activity of the molecule.
Except for compounds 7, 17, 18, 22, and 26, most compounds were poorly soluble (<5 μM). As previously noted, a methyl group has no significant effect on the activity but its presence in compounds 7 and 22 significantly increases the solubility (130 and 190 μM, respectively) most likely by the disruption of the crystalline packing [35,36]. The high solubility of compounds 17 and 26 (185 and 200 μM) may be attributed to a combination of steric and polar effect of the electronegative oxygen atoms.

4. Materials and Methods

4.1. General

All commercially available chemicals were purchased from local chemical suppliers. Analytical thin-layer chromatography (TLC) was performed on aluminium-backed silica-gel 60 F254 (70–230 mesh) plates. Flash column chromatography was performed with Merck silica-gel 60 (70–230 mesh) on a Biotage Isolera ™ system (Biotage AB, Uppsala, Sweden). Products were characterized by 1H- and 13C-NMR spectra recorded on a 300 MHz, 400 MHz or 600 MHz Varian or Bruker NMR spectrometers. Chemical shifts (δ) are given in ppm downfield from trimethylsilane (TMS) as the internal standard. Coupling constants (J), are recorded in hertz (Hz). Purity was determined by HPLC. The NMR spectra and HPLC-MS spectra of compounds described in this study can be found in Supplementary Materials.
Aqueous solubility. Water solubility was analyzed using a miniaturized shake flask method. Ten millimolar stock solutions of each of the compounds were used to prepare calibration standards (10−220 μM) in DMSO. The same 10 mM stock solutions were accurately dispensed in duplicate into 96-well plates, and the DMSO, dried down (MiVac GeneVac,90 min, 37 °C). Thereafter, the samples were reconstituted (200 μM) in an aqueous solution and shaken (20 h, 25 °C). The solutions were analyzed by means of HPLC-DAD (Agilent1200 Rapid Resolution HPLC with a diode array detector). Best fit calibration curves were constructed using the calibration standards, which were used to determine the aqueous samples’ solubility [1,37].
In-vitro anti-plasmodium assay. Compounds were tested using parasite lactate dehydrogenase assay as a marker for parasite survival. The respective stock solutions of CQ diphosphate and test compounds were prepared by dissolving 2 mg/mL in distilled water (for CQ) and 100% DMSO for test compounds. The solutions were then stored at −20 °C, with further dilutions prepared on the day of the experiment. The cultures were synchronized in the ring stage as described previously using 15 mL of 5% (w/v) d-sorbitol in water. Synchronous cultures of PfNF54 (CQS) in the late trophozoite stage were prepared to 2% parasitemia and 2% hematocrit. Compounds were tested at starting concentrations of 10 000 ng/mL (1000 ng/mL for CQ), which were then serially diluted two-fold in complete medium to give 10 concentrations with a final volume of 200 μL in each well. Parasites were incubated in the presence of the compounds at 37 °C in a specialized atmosphere of 4% CO2 and 3% O2 in nitrogen for 48 h. Following incubation, 100 μL of MalStat reagent and 15 μL of resuspended culture were combined, followed by addition of 25 μL of nitro blue tetrazolium chloride (NBT). The plates were kept in the dark for about 10 min to fully develop, and absorbance was measured at 620 nm on a microplate reader. Raw data were exported to Microsoft Excel for dose-response analysis [1,37].
Cytotoxicity assay. Compounds were screened for in vitro cytotoxicity against Chinese hamster ovarian (CHO) mammalian cell lines, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The reference standard, emetine, was prepared to 2 mg/mL in distilled water while stock solutions of test compounds were prepared to 20 mg/mL in 100% DMSO with the highest concentration of solvent to which the cells were exposed having no measurable effect on the cell viability. The initial concentration of the compounds and control was 100 μg/mL, which was serially diluted in complete medium with 10-fold dilutions to give six concentrations, the lowest being 0.001 μg/mL. Plates were incubated for 48 h with 100 μL of drug and 100 μL of cell suspension in each well and developed afterward by adding 25 μL of sterile MTT (Thermo Fisher Scientific) to each well, followed by 4 h of incubation in the dark. The plates were then centrifuged; the medium was aspirated, and 100 μL of DMSO was added to dissolve crystals before reading the absorbance at 540 nm. Data were analyzed, and the sigmoidal dose-response was derived using GraphPad Prism v 4.0 software (La Jolla). All experiments were performed for at least three independent biological repeats, each with technical triplicates [1].

4.2. Experimental Section

General procedure for preparing 4-acetyl-N-(((7-chloroquinolin-4-yl)amino)alkyl) benzenesulfonamides 4 and 5: 4-acetylbenzenesulfonyl chloride was treated with the respective N-(7-chloroquinolin-4-yl) alkyldiamine (2 or 3) in 7.5 mL dioxane as solvent and 2.5 mL 10 M NaOH. The reaction mixture was stirred at room temperature for 24 h and poured into 50 mL of ice-cold water. The precipitate was filtered, dried and the crude product purified using Biotage Isolera One® column chromatography in a gradient mixture of CH2Cl2/MeOH. Fractions were monitored and collected at 254 and 280 nm. The solvent of the combined fractions was removed under reduced pressure to afford compounds 4 and 5 as white solids in 27 and 41% yield, respectively.
4-acetyl-N-(2-((7-chloroquinolin-4-yl)amino)ethyl)benzenesulfonamide (4); white solid (0.97 g, 27%); m.p. 200–204 °C; Rf = 0.61 (MeOH-CH2Cl2 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.35 (d, J = 5.4 Hz, 1H), 8.09 (d, J = 9.1 Hz, 1H), 8.01 (t, J = 5.7 Hz, 1H), 7.99–7.94 (m, 2H), 7.90–7.84 (m, 2H), 7.75 (d, J = 2.2 Hz, 1H), 7.43 (dd, J = 9.0, 2.3 Hz, 1H), 7.23 (t, J = 5.8 Hz, 1H), 6.40 (d, J = 5.5 Hz, 1H), 3.37 (q, J = 6.3 Hz, 2H), 3.10 (t, J = 6.1 Hz, 2H), 2.56 (s, 3H). 13C NMR (151 MHz, DMSO-d6) δ 197.48, 152.10, 150.20, 149.24, 144.55, 139.67, 133.99, 129.31, 127.81, 127.15, 124.63, 124.38, 117.81, 99.02, 42.46, 41.26, 27.34; HPLC-MS (APCI/ESI): Purity = 80%. tR = 0.898 min, calcd. m/z = 403.88, m/z [M]+ = 404.0.
4-acetyl-N-(3-((7-chloroquinolin-4-yl)amino)propyl)benzenesulfonamide (5); white solid (0.144 g, 41%); m.p. 181–183 °C; Rf = 0.46 (MeOH-CH2Cl2,1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.36 (d, J = 5.4 Hz, 1H), 8.19 (d, J = 9.0 Hz, 1H), 8.08–8.03 (m, 2H), 7.92–7.84 (m, 3H), 7.77 (d, J = 2.2 Hz, 1H), 7.43 (dd, J = 9.0, 2.3 Hz, 1H), 7.21 (t, J = 5.5 Hz, 1H), 6.38 (d, J = 5.5 Hz, 1H), 3.24 (td, J = 6.9, 5.3 Hz, 2H), 2.97–2.90 (m, 2H), 2.59 (s, 3H), 1.77 (p, J = 7.0 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 197.64, 152.17, 150.45, 149.33, 144.60, 139.79, 133.90, 129.41, 127.83, 127.24, 124.55, 124.49, 117.85, 99.14, 40.57, 40.31, 28.22, 27.41; HPLC-MS (APCI/ESI): Purity = 100%. tR = 2.186 min, calcd. m/z = 417.91, m/z [M]+ = 418.0.
General procedure for the synthesis of molecular hybrids 6–27: To a solution of chloroquinolinesulfonamide (4 or 5) and aryl aldehyde derivatives in methanol (2 mL), NaOH (24 mg, 6 mmoles, 2.5 equiv.) was added. The reaction mixture was stirred under reflux overnight. The product was purified using Biotage Isolera One ® column chromatography in a gradient mixture of CH2Cl2/MeOH. Fractions were monitored and collected at 254 and 280 nm. The solvent of the combined fractions was removed under reduced pressure. In some cases, the products were further purified by recrystallization in CH2Cl2 and MeOH to afford crystalline solids with 11–88% yield.
N-(3-((7-chloroquinolin-4-yl)amino)propyl)-4-cinnamoylbenzenesulfonamide (6); white solid (0.087 g, 72%); m.p. 210–212 °C; Rf = 0.39 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.37 (d, J = 5.4 Hz, 1H), 8.28–8.23 (m, 2H), 8.21 (d, J = 9.1 Hz, 1H), 7.97–7.92 (m, 2H), 7.92–7.88 (m, 3H), 7.88 (d, J = 13.5 Hz, 1H), 7.78 (d, J = 15.7 Hz, 1H), 7.76 (d, J = 2.2 Hz, 1H), 7.64–7.58 (m, 1H), 7.53–7.46 (m, 2H), 7.46–7.36 (m, 1H), 7.30 (t, J = 5.4 Hz, 1H), 6.40 (d, J = 5.5 Hz, 1H), 3.25 (q, J = 6.6 Hz, 2H), 2.96 (q, J = 6.7 Hz, 2H), 1.79 (p, J = 7.0 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 188.99, 167.83, 151.87, 150.65, 145.48, 144.52, 140.76, 134.96, 134.06, 133.24, 131.39, 129.77, 129.71, 127.55, 127.31, 124.64, 124.54, 122.35, 117.79, 99.14, 41.01, 40.56, 28.25; HPLC-MS (APCI/ESI): Purity = 100%. tR = 2.470 min, calcd. m/z = 506.0, m/z [M]+ = 506.0.
(E)-N-(3-((7-chloroquinolin-4-yl)amino)propyl)-4-(3-(p-tolyl)acryloyl)benzenesulfonamide (7); white solid (0.0738 g, 59%); m.p. 209–213 °C; Rf = 0.48 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.36 (d, J = 5.4 Hz, 1H), 8.27–8.22 (m, 2H), 8.20 (d, J = 9.0 Hz, 1H), 7.96–7.91 (m, 2H), 7.89 (t, J = 5.8 Hz, 1H), 7.83 (d, J = 15.6 Hz, 1H), 7.81–7.78 (m, 2H), 7.78–7.73 (m, 2H), 7.42 (dd, J = 9.0, 2.2 Hz, 1H), 7.30 (d, J = 7.9 Hz, 2H), 7.23 (t, J = 5.4 Hz, 1H), 6.39 (d, J = 5.5 Hz, 1H), 3.24 (t, J = 6.5 Hz, 2H), 2.96 (q, J = 6.7 Hz, 2H), 2.37 (s, 3H), 1.79 (q, J = 7.0 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 188.92, 152.13, 150.50, 149.28, 145.58, 144.43, 141.57, 140.90, 133.92, 132.26, 130.06, 129.71, 129.57, 127.79, 127.29, 124.56, 124.49, 121.28, 117.85, 99.15, 41.03, 40.17, 28.27, 21.60; HPLC-MS (APCI/ESI): Purity = 100%, tR = 2.528 min, calcd. m/z = 520.0, m/z [M]+ = 520.1.
(E)-4-(3-(2-bromophenyl)acryloyl)-N-(3-((7-chloroquinolin-4-yl)amino)propyl)benzenesulfonamide (8); white solid (0.1089 g, 78%); m.p. 211–213 °C; Rf = 0.48 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.36 (d, J = 5.4 Hz, 1H), 8.28–8.24 (m, 2H), 8.23–8.16 (m, 2H), 8.02 (d, J = 15.5 Hz, 1H), 7.95 (s, 1H), 7.94 (d, J = 2.0 Hz, 1H), 7.92–7.85 (m, 2H), 7.80–7.72 (m, 2H), 7.56–7.49 (m, 1H), 7.49–7.39 (m, 2H), 7.26–7.16 (m, 1H), 6.44–6.36 (m, 1H), 3.24 (q, J = 6.5 Hz, 2H), 2.96 (q, J = 6.6 Hz, 2H), 1.77 (h, J = 7.1 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 188.25, 151.78, 151.75, 149.91, 148.95, 144.22, 142.09, 139.90, 133.74, 133.33, 132.42, 129.39, 128.82, 128.24, 127.40, 126.82, 125.50, 124.62, 124.05, 123.95, 117.36, 98.64, 40.50, 40.46, 27.71; HPLC-MS (APCI/ESI): Purity = 100%. tR = 2.530 min, calcd. m/z = 584.9, m/z [M + H]+ = 585.9.
(E)-N-(3-((7-chloroquinolin-4-yl)amino)propyl)-4-(3-(4-fluorophenyl)acryloyl)benzenesulfonamide (9); white solid (0.0763 g, 61%); m.p. 216–218 °C; Rf = 0.46 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.37 (d, J = 5.5 Hz, 1H), 8.27–8.23 (m, 2H), 8.21 (d, J = 9.0 Hz, 1H), 8.02–7.73 (m, 8H), 7.44 (dd, J = 8.9, 2.2 Hz, 1H), 7.35–7.28 (m, 3H), 6.41 (d, J = 5.5 Hz, 1H), 3.26 (q, J = 6.5 Hz, 2H), 2.96 (q, J = 6.6 Hz, 2H), 1.78 (p, J = 7.0 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 188.86, 164.04 (d, JC-F = 249.6 Hz), 151.65, 150.78, 144.52, 144.23, 140.73, 134.17, 131.95, 131.93 (d, JC-F = 8.5 Hz), 131.68, 129.77, 127.34, 127.30, 124.71, 124.57, 122.23, 117.74, 116.47 (d, JC-F = 21.8 Hz), 99.14, 41.00, 40.23, 28.24. HPLC-MS (APCI/ESI); Purity = 100%, tR = 2.476 min, calcd. m/z = 524.0, m/z [M]+ = 524.0.
(E)-N-(3-((7-chloroquinolin-4-yl)amino)propyl)-4-(3-(2,6-difluorophenyl)acryloyl)benzenesulfonamide (10); white solid (0.1216 g, 70%); m.p. 223–225 °C; Rf = 0.44 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.34 (d, J = 5.3 Hz, 1H), 8.17 (d, J = 9.0 Hz, 1H), 8.15–8.11 (m, 2H), 7.97–7.92 (m, 2H), 7.90 (q, J = 5.5 Hz, 1H), 7.77 (s, 1H), 7.75–7.68 (m, 2H), 7.59 (tt, J = 8.2, 6.4 Hz, 1H), 7.40 (dd, J = 9.0, 2.3 Hz, 1H), 7.27 (t, J = 8.8 Hz, 2H), 7.16 (t, J = 5.5 Hz, 1H), 6.37 (d, J = 5.4 Hz, 1H), 3.23 (q, J = 6.5 Hz, 2H), 2.96 (q, J = 6.5 Hz, 2H), 1.78 (p, J = 6.9 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 188.48, 161.10 (d, JC-F = 253.9 Hz), 151.81, 149.92, 148.98, 144.27, 139.69, 133.32, 132.89 (t, JC-F = 11.2 Hz), 130.08, 129.20, 127.42, 127.17, 126.99, 124.02, 123.98, 117.39, 112.49, 112.32 (d, JC-F = 21.7 Hz), 98.63, 40.49, 40.04, 27.78. HPLC-MS (APCI/ESI); Purity = 100%, tR = 2.477 min, calcd. m/z = 542.0, m/z [M]+ = 542.0.
(E)-4-(3-(4-chlorophenyl)acryloyl)-N-(3-((7-chloroquinolin-4-yl)amino)propyl)benzenesulfonamide (11); white solid (0.045 g, 35%); m.p. 222–225 °C; Rf = 0.47 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.35 (d, J = 5.3 Hz, 1H), 8.27–8.23 (m, 2H), 8.18 (d, J = 9.0 Hz, 1H), 7.95 (s, 1H), 7.96–7.88 (m, 5H), 7.77 (d, J = 15.7 Hz, 1H), 7.74 (d, J = 2.2 Hz, 1H), 7.57–7.52 (m, 2H), 7.41 (dd, J = 9.0, 2.3 Hz, 1H), 7.18 (t, J = 5.4 Hz, 1H), 6.37 (d, J = 5.4 Hz, 1H), 3.23 (q, J = 6.5 Hz, 2H), 2.96 (t, J = 6.9 Hz, 2H), 1.78 (p, J = 7.0 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 188.36, 151.80, 149.87, 148.98, 144.08, 143.44, 140.11, 135.37, 133.44, 133.32, 130.69, 129.30, 128.96, 127.45, 126.79, 123.99, 123.93, 122.54, 117.37, 98.63, 48.55, 40.51, 27.73; HPLC-MS (APCI/ESI): Purity = 100%. tR = 2.527 min, calcd. m/z = 540.4, m/z [M]+ = 540.0.
(E)-N-(3-((7-chloroquinolin-4-yl)amino)propyl)-4-(3-(4-methoxyphenyl)acryloyl)benzenesulfonamide (12); white solid (0.0261 g, 20%); m.p. 221–223 °C; Rf = 0.45 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.36 (d, J = 5.4 Hz, 1H), 8.25–8.21 (m, 2H), 8.19 (d, J = 9.0 Hz, 1H), 7.98–7.91 (m, 2H), 7.91–7.84 (m, 3H), 7.75 (d, J = 3.0 Hz, 3H), 7.42 (dd, J = 9.0, 2.3 Hz, 1H), 7.20 (t, J = 5.5 Hz, 1H), 7.06–7.01 (m, 2H), 6.38 (d, J = 5.4 Hz, 1H), 3.83 (s, 3H), 3.26–3.21 (m, 2H), 2.96 (q, J = 6.6 Hz, 2H), 1.78 (p, J = 7.0 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 188.29, 161.63, 151.76, 149.93, 148.92, 145.05, 140.62, 133.38, 131.88, 131.00, 129.14, 127.40, 127.11, 126.77, 124.04, 123.96, 119.30, 117.37, 114.46, 98.65, 55.40, 54.85, 40.53, 27.76; HPLC-MS (APCI/ESI): Purity = 100%. tR = 2.471 min, calcd. m/z = 536.04, m/z [M]+ = 536.1.
(E)-N-(3-((7-chloroquinolin-4-yl)amino)propyl)-4-(3-(3,4-difluorophenyl)acryloyl)benzenesulfonamide (13); light yellow solid (0.0651 g, 38%); m.p. 212–214 °C; Rf = 0.43 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.35 (d, J = 5.4 Hz, 1H), 8.28–8.23 (m, 2H), 8.18 (d, J = 9.1 Hz, 1H), 8.13 (ddd, J = 12.1, 7.9, 2.1 Hz, 1H), 7.96–7.88 (m, 4H), 7.78–7.72 (m, 3H), 7.54 (dt, J = 10.6, 8.5 Hz, 1H), 7.41 (dd, J = 9.0, 2.3 Hz, 1H), 7.20 (t, J = 5.4 Hz, 1H), 6.37 (d, J = 5.4 Hz, 1H), 3.24 (q, J = 6.5 Hz, 2H), 2.97 (q, J = 6.5 Hz, 2H), 1.78 (p, J = 7.0 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 188.22, 151.71, 151.67, 149.9 (d, JC-F =10.9 Hz), 148.92 (d, JC-F = 13.3 Hz), 142.59, 140.01, 132.44 (d, JC-F = 2.8 Hz), 129.51, 129.34, 127.36, 127.0 (d, JC-F = 3.4 Hz), 126.98 (d, JC-F =6.9 Hz), 123.95, 123.01, 118.06,118.0 (d, JC-F = 17.4 Hz), 117.98, 117.35, 117.26, 117.08, 98.63, 40.51, 40.04, 27.73; HPLC-MS (APCI/ESI): Purity = 100%. tR = 2.475 min, calcd. m/z = 542.11, m/z [M]+ = 542.0.
(E)-N-(3-((7-chloroquinolin-4-yl)amino)propyl)-4-(3-(3,4-dimethoxyphenyl)acryloyl)benzenesulfonamide (14); white solid (0.0146 g, 11%); m.p. 222–224 °C; Rf = 0.37 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.36 (d, J = 5.4 Hz, 1H), 8.26–8.22 (m, 2H), 8.19 (d, J = 9.0 Hz, 1H), 7.96–7.91 (m, 2H), 7.89 (t, J = 5.7 Hz, 1H), 7.80–7.71 (m, 3H), 7.55 (d, J = 2.0 Hz, 1H), 7.45–7.39 (m, 2H), 7.20 (t, J = 5.5 Hz, 1H), 7.04 (d, J = 8.4 Hz, 1H), 6.38 (d, J = 5.5 Hz, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 3.24 (q, J = 6.5 Hz, 2H), 2.96 (q, J = 6.6 Hz, 2H), 1.78 (p, J = 7.0 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 188.33, 151.76, 151.58, 149.92, 149.03, 148.92, 145.57, 143.79, 140.67, 133.36, 129.14, 127.39, 127.29, 126.74, 124.25, 124.03, 123.95, 119.38, 117.37, 111.59, 110.96, 98.65, 55.75, 55.62, 40.52, 40.04, 27.76; HPLC-MS (APCI/ESI): Purity = 100%. tR = 2.417 min, calcd. m/z = 566.07, m/z [M]+ = 566.1.
(E)-N-(3-((7-chloroquinolin-4-yl)amino)propyl)-4-(3-(2-fluorophenyl)acryloyl)benzenesulfonamide (15); white solid (0.1093 g, 65%); m.p. 223–225 °C; Rf = 0.40 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.35 (d, J = 5.5 Hz, 1H), 8.25–8.22 (m, 2H), 8.22–8.16 (m, 1H), 8.14–8.06 (m, 1H), 7.94 (dd, J = 7.6, 5.9 Hz, 2H), 7.92–7.81 (m, 3H), 7.78–7.70 (m, 1H), 7.58–7.49 (m, 1H), 7.41 (dd, J = 9.0, 2.3 Hz, 1H), 7.37–7.31 (m, 2H), 7.24–7.16 (m, 1H), 6.37 (d, J = 5.4 Hz, 1H), 3.24 (p, J = 6.5, 6.1 Hz, 2H), 2.96 (q, J = 6.5 Hz, 2H), 1.78 (p, J = 7.1 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 188.31, 160.98 (d, JC-F = 252.0 Hz), 151.81, 149.93, 148.98, 144.20, 139.95, 136.08, 133.36, 132.99,132.96 (d, JC-F = 8.8 Hz), 129.29 (d, JC-F = 3.0 Hz), 127.42, 127.38 (d, JC-F = 9.4 Hz), 127.01, 126.75, 124.98 (d, JC-F = 3.3 Hz), 124.03, 122.07, 117.40, 116.11 (d, JC-F = 21.5 Hz), 98.67, 40.51, 40.04, 27.72. HPLC-MS (APCI/ESI); Purity = 100%, tR = 2.444 min, calcd. m/z = 524.0, m/z [M]+ = 524.1.
(E)-N-(3-((7-chloroquinolin-4-yl)amino)propyl)-4-(3-(3,4,5-trimethoxyphenyl)acryloyl)benzenesulfonamide (16); white solid (0.1088 g, 76%); m.p. 197–200 °C; Rf = 0.48 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.37 (d, J = 5.5 Hz, 1H), 8.24–8.18 (m, 3H), 7.96–7.91 (m, 3H), 7.89 (t, J = 5.8 Hz, 1H), 7.82–7.73 (m, 3H), 7.43 (dd, J = 9.0, 2.2 Hz, 1H), 7.30 (t, J = 5.5 Hz, 1H), 6.95 (d, J = 8.9 Hz, 1H), 6.40 (d, J = 5.5 Hz, 1H), 3.89 (s, 3H), 3.88 (s, 3H), 3.78 (s, 3H), 3.25 (t, J = 6.5 Hz, 2H), 2.96 (q, J = 6.6 Hz, 2H), 1.78 (p, J = 7.0 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 188.88, 156.58, 153.74, 151.86, 150.66, 148.96, 144.32, 142.24, 141.13, 139.99, 134.06, 129.60, 127.54, 127.29, 124.65, 124.53, 124.19, 121.27, 120.66, 117.79, 109.00, 99.14, 62.03, 60.96, 56.62, 41.02, 40.57, 28.26; HPLC-MS (APCI/ESI): Purity = 100%, tR = 2.459 min, calcd m/z = 596.1, m/z [M]+ = 596.0.
(E)-N-(2-((7-chloroquinolin-4-yl)amino)ethyl)-4-(3-(4-methoxyphenyl)acryloyl)benzenesulfonamide (17); yellow solid (0.1144 g, 89%); m.p. 222–225 °C; Rf = 0.38 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.36 (d, J = 5.3 Hz, 1H), 8.19–8.14 (m, 2H), 8.10 (d, J = 9.0 Hz, 1H), 8.04 (t, J = 5.9 Hz, 1H), 7.94–7.89 (m, 2H), 7.89–7.83 (m, 2H), 7.78–7.72 (m, 2H), 7.70 (d, J = 15.6 Hz, 1H), 7.43 (dd, J = 9.0, 2.2 Hz, 1H), 7.23 (t, J = 5.7 Hz, 1H), 7.06–7.01 (m, 2H), 6.41 (d, J = 5.5 Hz, 1H), 3.83 (s, 3H), 3.38 (q, J = 6.3 Hz, 2H), 3.11 (q, J = 6.3 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 188.64, 162.11, 152.19, 150.19, 149.36, 145.45, 144.25, 141.05, 133.96, 131.48, 129.56, 127.90, 127.63, 127.20, 124.62, 124.35, 119.78, 117.84, 114.95, 99.02, 55.91, 42.55, 41.29; HPLC-MS (APCI/ESI): Purity = 100%, tR = 2.440 min, calcd. m/z = 522.12, m/z [M]+ = 522.0.
(E)-N-(3-((7-chloroquinolin-4-yl)amino)propyl)-4-(3-(2,4-difluorophenyl)acryloyl)benzenesulfonamide (18); light yellow solid (0.01118 g, 65%); m.p. 216–218 °C; Rf = 0.39 MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.35 (dd, J = 5.4, 1.9 Hz, 1H), 8.25–8.16 (m, 3H), 8.07–8.03 (m, 1H), 7.94 (d, J = 8.3 Hz, 1H), 7.94–7.86 (m, 2H), 7.82–7.72 (m, 2H), 7.46–7.37 (m, 2H), 7.29–7.19 (m, 2H), 6.38 (dd, J = 5.5, 2.2 Hz, 1H), 3.24 (t, J = 6.4 Hz, 2H), 2.98–2.90 (m, 2H), 1.77 (h, J = 6.8 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 188.19, 162.54 (d, JC-F = 100.6 Hz), 161.32 (d, JC-F = 242.3 Hz), 151.64, 151.62, 149.97, 148.80, 144.18, 143.95, 133.42, 130.31, 129.10 (d, JC-F = 58.9 Hz), 128.91, 126.73, 124.06, 123.98, 123.60, 118.97 (d, JC-F = 3.7 Hz), 117.34, 112.65 (d, JC-F = 3.4 Hz), 112.50 (d, JC-F = 3.7 Hz), 98.64, 40.49, 39.90, 27.70; HPLC-MS (APCI/ESI): Purity = 96%, tR = 2.464 min, calcd. m/z = 541.99, m/z [M]+ = 542.0.
(E)-N-(2-((7-chloroquinolin-4-yl)amino)ethyl)-4-(3-(3,4-dimethoxyphenyl)acryloyl)benzenesulfonamide (19); yellow solid (0.0609 g, 45%); m.p. 223–225 °C; Rf = 0.44 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.36 (d, J = 5.4 Hz, 1H), 8.18 (d, J = 8.2 Hz, 2H), 8.09 (d, J = 9.0 Hz, 1H), 7.92 (d, J = 8.4 Hz, 2H), 7.77–7.71 (m, 3H), 7.54 (d, J = 2.0 Hz, 1H), 7.42 (ddd, J = 7.9, 5.9, 2.1 Hz, 2H), 7.22 (t, J = 5.8 Hz, 1H), 7.04 (d, J = 8.4 Hz, 1H), 6.41 (d, J = 5.4 Hz, 1H), 3.86 (s, 3H), 3.83 (s, 3H), 3.38 (q, J = 6.4 Hz, 2H), 3.17 (d, J = 4.7 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 188.24, 151.83, 151.79, 151.57, 149.65, 149.02, 145.49, 143.73, 140.64, 133.42, 129.08, 127.47, 127.31, 126.68, 124.33, 124.19, 123.83, 119.40, 117.35, 111.60, 110.98, 98.52, 55.75, 48.56, 42.04; HPLC-MS (APCI/ESI): Purity = 100%. tR = 2.387 min, calcd. m/z = 552.04, m/z [M]+ = 552.1.
(E)-N-(3-((7-chloroquinolin-4-yl)amino)propyl)-4-(3-(2,5-difluorophenyl)acryloyl)benzenesulfonamide (20); light yellow solid (0.1134 g, 66%); m.p. 219–221 °C; Rf = 0.39 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.35 (d, J = 5.5 Hz, 1H), 8.27–8.23 (m, 2H), 8.19 (d, J = 9.0 Hz, 1H), 8.11–8.02 (m, 1H), 7.99 (d, J = 15.7 Hz, 1H), 7.95–7.87 (m, 2H), 7.79 (dd, J = 15.8, 1.4 Hz, 1H), 7.77–7.71 (m, 1H), 7.46–7.37 (m, 3H), 7.24 (t, J = 5.5 Hz, 1H), 6.38 (d, J = 5.5 Hz, 1H), 3.24 (q, J = 6.6 Hz, 2H), 2.97 (q, J = 6.6 Hz, 2H), 1.78 (p, J = 7.0 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 188.07, 158.59 (d, JC-F = 180.3 Hz), 156.97 (d, JC-F = 188.9 Hz), 155.42, 151.50, 150.04, 148.63, 144.30, 139.72, 134.64, 133.47, 129.39, 127.22, 126.84, 125.00, 124.99 (d, JC-F = 3.5 Hz), 123.99, 119.44 (d, JC-F = 9.0 Hz), 117.30, 117.07 (d, JC-F = 8.9 Hz), 114.87 (d, JC-F = 2.6 Hz), 98.63, 40.46, 40.04, 27.73; HPLC-MS (APCI/ESI): Purity = 100%. tR = 2.490 min, calcd. m/z = 542.11, m/z [M]+ = 542.0.
(E)-N-(3-((7-chloroquinolin-4-yl)amino)propyl)-4-(3-(furan-2-yl)acryloyl)benzenesulfonamide (21); light yellow solid (0.0798 g, 50%); m.p. 222–224 °C; Rf = 0.41 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.36 (d, J = 5.5 Hz, 1H), 8.21 (d, J = 9.0 Hz, 1H), 8.18–8.14 (m, 2H), 7.97–7.91 (m, 2H), 7.93–7.85 (m, 2H), 7.76 (d, J = 2.2 Hz, 1H), 7.60 (d, J = 15.4 Hz, 1H), 7.44 (dd, J = 9.4, 7.1 Hz, 1H), 7.15 (d, J = 3.4 Hz, 1H), 6.72 (dd, J = 3.5, 1.8 Hz, 1H), 6.40 (d, J = 5.6 Hz, 1H), 3.27–3.21 (m, 2H), 2.95 (q, J = 6.6 Hz, 2H), 1.78 (p, J = 6.9 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 187.89, 151.21, 150.98, 150.24, 148.29, 146.57, 143.89, 140.21, 133.63, 131.27, 129.05, 126.91, 126.88, 124.19, 124.05, 118.39, 117.83, 117.25, 113.27, 98.63, 48.56, 40.48, 27.72. HPLC-MS (APCI/ESI); Purity = 100%, tR = 2.368 min, calcd. m/z = 495.97, m/z [M]+ = 496.0.
(E)-N-(2-((7-chloroquinolin-4-yl)amino)ethyl)-4-(3-(p-tolyl)acryloyl)benzenesulfonamide (22); yellow solid (0.0704 g, 56%); m.p. 184–187 °C; Rf = 0.39 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.36 (d, J = 5.4 Hz, 1H), 8.20–8.14 (m, 2H), 8.10 (d, J = 9.1 Hz, 1H), 8.05 (t, J = 5.9 Hz, 1H), 7.94–7.89 (m, 2H), 7.82–7.71 (m, 5H), 7.43 (dd, J = 9.0, 2.2 Hz, 1H), 7.33–7.23 (m, 3H), 6.41 (d, J = 5.5 Hz, 1H), 3.38 (q, J = 6.3 Hz, 2H), 3.11 (q, J = 6.3 Hz, 2H), 2.36 (s, 3H). 13C NMR (151 MHz, DMSO-d6) δ 188.77, 152.10, 150.25, 149.25, 145.49, 144.38, 141.55, 140.81, 134.01, 132.27, 130.06, 129.63, 129.55, 127.81, 127.21, 124.64, 124.37, 121.24, 117.82, 99.02, 42.54, 41.29, 21.60; HPLC-MS (APCI/ESI): Purity = 100%, tR = 2.481 min, calcd. m/z = 506.02, m/z [M]+ = 506.0.
(E)-N-(2-((7-chloroquinolin-4-yl)amino)ethyl)-4-(3-ferrocenyl)acryloyl)benzenesulfonamide 23; purple solid (0.0601 g, 41%); m.p. 222–224 °C; Rf = 0.39 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.41 (d, J = 7.5 Hz, 1H), 8.17–7.19 (m, 14H), 6.56–6.47 (m, 6H), 3.15 (q, J = 6.6 Hz, 2H), 2.95 (q, J = 6.6 Hz, 2H), 1.76 (p, J = 7.1 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 187.29, 151.60, 149.75, 147.70, 143.47, 140.72, 133.16, 132.01, 128.84, 127.47, 126.63, 123.90, 118.48, 78.66, 71.51, 69.54, 69.35, 54.73, 48.44, 27.65; HPLC-MS (APCI/ESI): Purity = 100%, tR = 2.498 min, calcd. m/z = 613.9, m/z [M]+ = 614.0.
(E)-N-(2-((7-chloroquinolin-4-yl)amino)ethyl)-4-(3-(4-fluorophenyl)acryloyl)benzenesulfonamide (24); light yellow solid (0.0893 g, 71%); m.p. 222–224 °C Rf = 0.45 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.37 (d, J = 5.5 Hz, 1H), 8.20–8.14 (m, 2H), 8.10 (d, J = 9.1 Hz, 1H), 8.05 (t, J = 5.9 Hz, 1H), 8.03–7.95 (m, 2H), 7.94–7.89 (m, 2H), 7.84–7.71 (m, 3H), 7.43 (dd, J = 9.0, 2.3 Hz, 1H), 7.36–7.28 (m, 3H), 6.42 (d, J = 5.5 Hz, 1H), 3.39 (q, J = 6.3 Hz, 2H), 3.12 (q, J = 6.3 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 188.71, 163.22 (d, JC-F = 249.6 Hz), 151.83, 150.41, 148.92, 144.48, 144.14, 134.14, 131.93 (d, JC-F = 8.5 Hz), 131.88, 131.68, 129.68, 127.21, 124.72, 124.42, 122.17, 117.75, 116.54 (d, JC-F = 21.8 Hz), 116.40, 99.02, 42.55, 41.30; HPLC-MS (APCI/ESI): Purity = 100%, tR = 2.427 min, calcd. m/z = 509.98, m/z [M]+ = 510.0.
(E)-4-(3-(2-chlorophenyl)acryloyl)-N-(2-((7-chloroquinolin-4-yl)amino)ethyl)benzenesulfonamide (25); light yellow solid (0.0508 g, 39%); m.p. 209–211 °C Rf = 0.42 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.43 (td, J = 8.7, 5.9 Hz, 1H), 8.30–8.25 (m, 2H), 8.25–6.90 (m, 12H), 6.75 (d, J = 9.7 Hz, 1H), 6.55 (d, J = 9.1 Hz, 1H), 3.45 (dd, J = 12.1, 5.8 Hz, 2H), 3.07 (q, J = 6.3 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 192.18, 144.60, 139.91, 138.38, 134.46, 132.86, 132.51, 131.08, 130.64, 130.00, 129.74, 129.60, 128.22, 127.39, 127.19, 126.90, 125.90, 125.55, 124.93, 124.13, 121.62, 99.04, 42.75, 41.23; HPLC-MS (APCI/ESI): Purity = 82%, tR = 2.451 min, calcd. m/z = 526.4, m/z [M]+ = 526.0.
(E)-4-(3-(benzo[d][1,3]dioxol-5-yl)acryloyl)-N-(3-((7-chloroquinolin-4-yl)amino)propyl)benzenesulfonamide (26); yellow solid (0.058 g, 66%); m.p. 222–224 °C; Rf = 0.46 (MeOH-CH2Cl2, 1:9); 1H NMR (600 MHz, DMSO-d6) δ 8.35 (d, J = 5.4 Hz, 1H), 8.25 (d, J = 8.2 Hz, 2H), 8.19 (d, J = 9.0 Hz, 1H), 7.94–7.64 (m, 7H), 7.42 (dd, J = 9.0, 2.3 Hz, 1H), 7.36 (dd, J = 8.1, 1.7 Hz, 1H), 7.19 (t, J = 5.6 Hz, 1H), 7.01 (d, J = 8.0 Hz, 1H), 6.38 (d, J = 5.5 Hz, 1H), 6.12 (s, 2H), 3.24 (q, J = 6.5 Hz, 2H), 2.96 (q, J = 6.6 Hz, 2H), 1.78 (p, J = 7.1 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 188.16, 151.79, 149.89, 149.85, 148.97, 148.12, 145.05, 143.86, 140.50, 133.34, 129.17, 129.00, 127.43, 126.75, 126.30, 124.01, 123.94, 119.71, 117.38, 108.55, 107.02, 101.72, 98.64, 40.53, 40.48, 27.76. HPLC-MS (APCI/ESI); Purity = 100%, tR = 2.423 min, calcd. m/z = 550.0, m/z [M]+ = 550.0.
(E)-N-(3-((7-chloroquinolin-4-yl)amino)propyl)-4-(3-(4-(trifluoromethoxy)phenyl)acryloyl)benzenesulfonamide (27); light yellow solid (0.0901 g, 96% yield); m.p. 223–225 °C; Rf = 0.43 (10% MeOH-CH2Cl2); 1H NMR (600 MHz, DMSO-d6) δ 8.36 (d, J = 5.5 Hz, 1H), 8.27–8.23 (m, 2H), 8.20 (d, J = 8.9 Hz, 1H), 8.10–8.02 (m, 2H), 7.96–7.86 (m, 4H), 7.79 (d, J = 15.7 Hz, 1H), 7.74 (d, J = 2.3 Hz, 1H), 7.49–7.41 (m, 2H), 7.30 (t, J = 5.3 Hz, 1H), 6.40 (d, J = 5.5 Hz, 1H), 3.25 (q, J = 6.6 Hz, 2H), 2.96 (q, J = 6.5 Hz, 2H), 1.78 (p, J = 7.1 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 188.41, 151.30, 150.20, 149.74, 148.38, 144.12, 143.13, 140.08, 134.20, 133.61, 130.99, 129.33(d, JC-F = 25.3 Hz), 126.97, 126.74, 124.17, 124.04, 123.00, 121.26, 117.42, 117.27, 98.64, 40.49, 40.04, 27.72; HPLC-MS (APCI/ESI): Purity = 100%. tR = 2.559 min, MW = 590.1, m/z [M]+ = 590.0.

5. Conclusions

In conclusion, 22 molecular hybrids were successfully synthesized in good to excellent yields. They were all fully characterized using spectroscopic techniques such as 1H- and 13C-NMR spectroscopy and HPLC-MS. These compounds were evaluated for in vitro antiplasmodial activity against the chloroquine sensitive (NF54) strain of P. falciparum and displayed promising activity with IC50 values ranging at 0.10–4.45 μM. The frontrunner compound 12 showed improved resistivity index compared to CQ, as well as good safety profile (SI = 393.6).

Supplementary Materials

The following are available online. The NMR spectra and HPLC-MS spectra of compounds described in this study are available online.

Author Contributions

Conceptualization, W.M.; methodology, W.M.; validation, G.A.D., W.M.; formal analysis, B.V., G.A.D. and W.M.; investigation, B.V., G.A.D. and W.M.; resources, W.M.; data curation, B.V., G.A.D. and W.M.; writing—original draft preparation, W.M.; writing—review and editing, G.A.D., W.M.; supervision, G.A.D., W.M.; project administration, W.M.; funding acquisition, W.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the South African Medical Research Council and The Directorate of Research and Innovation of Walter Sisulu University.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

The logistical support received from the Drug Discovery and Development Centre (H3D) at the University of Cape Town is gratefully acknowledged.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds are available from the authors.

References

  1. Mueller, R.; Reddy, V.; Nchinda, A.T.; Mebrahtu, F.; Taylor, D.; Lawrence, N.; Tanner, L.; Barnabe, M.; Eyermann, C.J.; Zou, B.; et al. Lerisetron Analogues with Antimalarial Properties: Synthesis, Structure–Activity Relationship Studies, and Biological Assessment. ACS Omega 2020, 5, 6967–6982. [Google Scholar] [CrossRef]
  2. Kumar, S.; Singh, R.K.; Sharma, R.; Murthy, R.; Bhardwaj, T. Design, synthesis and evaluation of antimalarial potential of polyphosphazene linked combination therapy of primaquine and dihydroartemisinin. Eur. J. Pharm. Sci. 2015, 66, 123–137. [Google Scholar] [CrossRef]
  3. Rudrapal, M.; Chetia, D. Endoperoxide antimalarials: Development, structural diversity and pharmacodynamic aspects with reference to 1,2,4-trioxane-based structural scaffold. Drug Des. Dev. Ther. 2016, 10, 3575–3590. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. WHO. The “World Malaria Report 2020” at a Glance. 2020. Available online: https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2020 (accessed on 25 May 2021).
  5. WHO. The “World Malaria Report 2019” at a Glance. 2019. Available online: https://www.who.int/news-room/feature-stories/detail/world-malaria-report-2019 (accessed on 25 May 2021).
  6. Sherman, I.W. Malaria: Parasite Biology, Pathogenesis and Protection, in Malaria: Parasite Biology, Pathogenesis and Protection; ASM Press: Washington, DC, USA, 1998. [Google Scholar]
  7. Pinheiro, L.C.D.S.; Boechat, N.; Ferreira, M.D.L.G.; Júnior, C.C.; Jesus, A.M.; Leite, M.M.; Souza, N.B.; Krettli, A.U. Anti- Plasmodium falciparum activity of quinoline–sulfonamide hybrids. Bioorgan. Med. Chem. 2015, 23, 5979–5984. [Google Scholar] [CrossRef] [PubMed]
  8. Guantai, E.M.; Ncokazi, K.; Egan, T.J.; Gut, J.; Rosenthal, P.J.; Smith, P.J.; Chibale, K. Design, synthesis and in vitro antimalarial evaluation of triazole-linked chalcone and dienone hybrid compounds. Bioorgan. Med. Chem. 2010, 18, 8243–8256. [Google Scholar] [CrossRef] [PubMed]
  9. Smit, F.J.; Van Biljon, R.; Birkholtz, L.-M.; N’Da, D.D. Synthesis and in vitro biological evaluation of dihydroartemisinyl-chalcone esters. Eur. J. Med. Chem. 2015, 90, 33–44. [Google Scholar] [CrossRef] [PubMed]
  10. Muregi, F.W.; Ishih, A. Next-generation antimalarial drugs: Hybrid molecules as a new strategy in drug design. Drug Dev. Res. 2009, 71, 20–32. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Viegas-Junior, C.; Danuello, A.; da Silva Bolzani, V.; Barreiro, E.J.; Fraga, C.A.M. Molecular Hybridization: A Useful Tool in the Design of New Drug Prototypes. Curr. Med. Chem. 2007, 14, 1829–1852. [Google Scholar] [CrossRef]
  12. Vandekerckhove, S.; D’Hooghe, M. Quinoline-based antimalarial hybrid compounds. Bioorgan. Med. Chem. 2015, 23, 5098–5119. [Google Scholar] [CrossRef]
  13. Lopez, S.N.; Castelli, M.V.; Zacchino, S.A.; Domınguez, J.N.; Lobo, G.; Charris-Charris, J.; Cortes, J.G.; Ribas, J.C.; Devia, C.; Rodrıguez, A.M.; et al. In vitro antifungal evaluation and structure–activity relationships of a new series of chalcone derivatives and synthetic analogues, with inhibitory properties against polymers of the fungal cell wall. Bioorgan. Med. Chem. 2001, 9, 1999–2013. [Google Scholar] [CrossRef]
  14. Konieczny, M.T.; Horowska, B.; Kunikowski, A.; Konopa, J.; Wierzba, K.; Yamada, Y.; Asao, T. Synthesis of Polyhydroxylated Derivatives of Phenyl Vinyl Sulfone as Structural Analogs of Chalcones. Synthesis 2001, 2001, 1363–1367. [Google Scholar] [CrossRef]
  15. Go, M.L.; Wu, X.; Liu, X.L. Chalcones: An Update on Cytotoxic and Chemoprotective Properties. Curr. Med. Chem. 2005, 12, 483–499. [Google Scholar] [CrossRef] [PubMed]
  16. Barfod, L.; Kemp, K.; Hansen, M.; Kharazmi, A. Chalcones from Chinese liquorice inhibit proliferation of T cells and production of cytokines. Int. Immunopharmacol. 2002, 2, 545–555. [Google Scholar] [CrossRef]
  17. Tomar, V.; Bhattacharjee, G.; Kamaluddin; Rajakumar, S.; Srivastava, K.; Puri, S. Synthesis of new chalcone derivatives containing acridinyl moiety with potential antimalarial activity. Eur. J. Med. Chem. 2010, 45, 745–751. [Google Scholar] [CrossRef]
  18. Ducki, S.; Forrest, R.; Hadfield, J.A.; Kendall, A.; Lawrence, N.J.; McGown, A.T.; Rennison, D. Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorgan. Med. Chem. Lett. 1998, 8, 1051–1056. [Google Scholar] [CrossRef]
  19. Parmar, V.S.; Sharma, N.K.; Husain, M.; Watterson, A.C.; Kumar, J.; A Samuelson, L.; Cholli, A.L.; Prasad, A.K.; Malhotra, S.; Kumar, N.; et al. Synthesis, characterization and in vitro anti-invasive activity screening of polyphenolic and heterocyclic compounds. Bioorgan. Med. Chem. 2003, 11, 913–929. [Google Scholar] [CrossRef]
  20. Mukherjee, S.; Kumar, V.; Prasad, A.K.; Raj, H.G.; Bracke, M.E.; Olsen, C.E.; Jain, S.C.; Parmar, V.S. Synthetic and biological activity evaluation studies on novel 1,3-diarylpropenones. Bioorgan. Med. Chem. 2001, 9, 337–345. [Google Scholar] [CrossRef]
  21. Hsieh, H.-K.; Tsao, L.-T.; Wang, J.-P.; Lin, C.-N. Synthesis and Anti-inflammatory Effect of Chalcones. J. Pharm. Pharmacol. 2010, 52, 163–171. [Google Scholar] [CrossRef] [PubMed]
  22. Hsieh, H.; Lee, T.; Wang, J.; Wang, J.; Lin, C. Synthesis and Anti-inflammatory Effect of Chalcones and Related Compounds. Pharm. Res. 1998, 15, 39–46. [Google Scholar] [CrossRef]
  23. Liu, M.; Wilairat, P.; Go, M.-L. Antimalarial Alkoxylated and Hydroxylated Chalones: Structure−Activity Relationship Analysis. J. Med. Chem. 2001, 44, 4443–4452. [Google Scholar] [CrossRef]
  24. Gutteridge, C.E.; Nichols, D.A.; Curtis, S.M.; Thota, D.S.; Vo, J.V.; Gerena, L.; Montip, G.; Asher, C.O.; Diaz, D.S.; DiTusa, C.A.; et al. In vitro and in vivo efficacy and in vitro metabolism of 1-phenyl-3-aryl-2-propen-1-ones against Plasmodium falciparum. Bioorgan. Med. Chem. Lett. 2006, 16, 5682–5686. [Google Scholar] [CrossRef] [PubMed]
  25. Yadav, N.; Dixit, S.K.; Bhattacharya, A.; Mishra, L.C.; Sharma, M.; Awasthi, S.K.; Bhasin, V.K. Antimalarial Activity of Newly Synthesized Chalcone Derivatives In Vitro. Chem. Biol. Drug Des. 2012, 80, 340–347. [Google Scholar] [CrossRef]
  26. Bondock, S.; Gieman, H.; El-Shafei, A. Selective synthesis, structural studies and antitumor evaluation of some novel unsymmetrical 1-hetaryl-4-(2-chloroquinolin-3-yl)azines. J. Saudi Chem. Soc. 2016, 20, 695–702. [Google Scholar] [CrossRef] [Green Version]
  27. Aminake, M.N.; Mahajan, A.; Kumar, V.; Hans, R.; Wiesner, L.; Taylor, D.; de Kock, C.; Grobler, A.; Smith, P.J.; Kirschner, M.; et al. Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy. Bioorgan. Med. Chem. 2012, 20, 5277–5289. [Google Scholar] [CrossRef] [PubMed]
  28. Walsh, J.J.; Coughlan, D.; Heneghan, N.; Gaynor, C.; Bell, A. A novel artemisinin–quinine hybrid with potent antimalarial activity. Bioorgan. Med. Chem. Lett. 2007, 17, 3599–3602. [Google Scholar] [CrossRef]
  29. Nqoro, X.; Tobeka, N.; Aderibigbe, B.A. Quinoline-Based Hybrid Compounds with Antimalarial Activity. Molecules 2017, 22, 2268. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  30. Verma, S.; Deshpande, S.; Pandey, S.; Agarwal, P.; Saxena, J.K.; Srivastava, K.; Chauhan, P.M.S.; Prabhakar, Y.S. N-(7-Chloroquinolinyl-4-aminoalkyl)arylsulfonamides as antimalarial agents: Rationale for the activity with reference to inhibition of hemozoin formation. RSC Adv. 2016, 6, 25584–25593. [Google Scholar] [CrossRef]
  31. Soares, R.R.; da Silva, J.M.F.; Carlos, B.C.; da Fonseca, C.C.; de Souza, L.S.A.; Lopes, F.V.; Dias, R.M.D.P.; Moreira, P.O.L.; Abramo, C.; Viana, G.H.R.; et al. New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo. Bioorgan. Med. Chem. Lett. 2015, 25, 2308–2313. [Google Scholar] [CrossRef]
  32. Fisher, G.M.; Tanpure, R.P.; Douchez, A.; Andrews, K.T.; Poulsen, S.-A. Synthesis and Evaluation of Antimalarial Properties of Novel 4-Aminoquinoline Hybrid Compounds. Chem. Biol. Drug Des. 2014, 84, 462–472. [Google Scholar] [CrossRef]
  33. Salahuddin, A.; Inam, A.; Van Zyl, R.; Heslop, D.C.; Chen, C.-T.; Avecilla, F.; Agarwal, S.M.; Azam, A. Synthesis and evaluation of 7-chloro-4-(piperazin-1-yl)quinoline-sulfonamide as hybrid antiprotozoal agents. Bioorgan. Med. Chem. 2013, 21, 3080–3089. [Google Scholar] [CrossRef]
  34. Pandey, S.; Agarwal, P.; Srivastava, K.; Rajakumar, S.; Puri, S.K.; Verma, P.; Saxena, J.; Sharma, A.; Lal, J.; Chauhan, P.M. Synthesis and bioevaluation of novel 4-aminoquinoline-tetrazole derivatives as potent antimalarial agents. Eur. J. Med. Chem. 2013, 66, 69–81. [Google Scholar] [CrossRef] [PubMed]
  35. Ishikawa, M.; Hashimoto, Y.J. Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry. Med. Chem. 2011, 54, 1539–1554. [Google Scholar] [CrossRef] [PubMed]
  36. Zhou, L.; Yang, L.; Tilton, S.; Wang, J. Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery. J. Pharm. Sci. 2007, 96, 3052–3071. [Google Scholar] [CrossRef] [PubMed]
  37. Makler, M.T.; Piper, R.; Williams, J.A.; Gibbins, B.L.; Hinrichs, D.J.; Ries, J.M.; Bancroft, J.E. Parasite Lactate Dehydrogenase as an Assay for Plasmodium falciparum Drug Sensitivity. Am. J. Trop. Med. Hyg. 1993, 48, 739–741. [Google Scholar] [CrossRef] [PubMed]
Molecules 26 04093 g001 550
Figure 1. Structures of licochalcone (I) and molecular hybrids II–V.
Figure 1. Structures of licochalcone (I) and molecular hybrids II–V.
Molecules 26 04093 g001
Molecules 26 04093 g002 550
Figure 2. Representative quinoline–sulfonamide molecular hybrids VI–X.
Figure 2. Representative quinoline–sulfonamide molecular hybrids VI–X.
Molecules 26 04093 g002
Molecules 26 04093 sch001 550
Scheme 1. Synthesis of molecular hybrids 1–2. Reagents and conditions: (i) appropriate diamine, reflux, 16 h; (ii) 4-acetylbenzenesulfonyl chloride, dioxane, NaOH, rt, 24 h; (iii) benzaldehyde derivative, MeOH, NaOH, reflux overnight.
Scheme 1. Synthesis of molecular hybrids 1–2. Reagents and conditions: (i) appropriate diamine, reflux, 16 h; (ii) 4-acetylbenzenesulfonyl chloride, dioxane, NaOH, rt, 24 h; (iii) benzaldehyde derivative, MeOH, NaOH, reflux overnight.
Molecules 26 04093 sch001
Table
Table 1. Hybrid compounds with isolated yields.
Table 1. Hybrid compounds with isolated yields.
Molecules 26 04093 i001
CompoundnArYield (%)
42-29
53-41
63Ph72
734-Me-Ph59
832-Br-Ph78
934-F-Ph61
1032,6-F2-Ph70
1134-Cl-Ph35
1234-OMe-Ph20
1333,4-F2-Ph65
1433,4-(OMe)2-Ph11
1532-F-Ph66
1633,4,5-(OMe)3-Ph76
1724-OMe-Ph89
1832,4-F2-Ph38
1923,4-(OMe)2-Ph45
2032,5-F2-Ph66
2132-furanyl50
2224-Me-Ph56
233ferrocenyl31
2424-F-Ph71
2522-Cl-Ph39
2633,4-OCH2O-Ph66
2734-OCF3-Ph96
Table
Table 2. In vitro antiplasmodial activity, solubility, and cytotoxicity of the hybrid compounds.
Table 2. In vitro antiplasmodial activity, solubility, and cytotoxicity of the hybrid compounds.
Molecules 26 04093 i002
CompoundnArPfNF54
IC50 (μM) a		Solubility b (μM)
pH 6.5 		CHO
IC50 (μM) c		SI d
Chloroquine--0.011 --
Emetine 0.0034
42-0.4520026.3258.4
53-0.48<5>50>104
63Ph1.67ND>50>29
734-Me-Ph0.3713025.0867.8
832-Br-Ph0.10ND43.25435
934-F-Ph0.28<514.6552.5
1032,6-F2-Ph0.54<527.6251.1
1134-Cl-Ph0.10ND41.2416.2
1234-OMe-Ph0.11ND43.3393.6
1333,4-F2-Ph2.58<5>300>116
1433,4-(OMe)2-Ph0.32ND43.4135.6
1532-F-Ph0.86545.5352.9
1632,3,4-(OMe)3-Ph0.581522.6239.0
1724-OMe-Ph0.4918517.5335.7
1832,4-F2-Ph0.5013022.4445.2
1923,4-(OMe)2-Ph0.33ND45.1136.7
2032,5-F2-Ph0.79 43.755.3
21 32-furanyl4.45200>50>11
2224-Me-Ph0.3919024.8963.8
233ferrocenyl1.53ND ND
2424-F-Ph0.57<514.5425.5
2522-Cl-Ph0.371935.4195.7
2633,4-OCH2O-Ph0.6920034.1349.5
2734-OCF3-Ph0.51ND44.0486.3
a Mean from n values of ≥2 independent experiments with sensitive (NF54) strains of P. falciparum; b Aqueous solubility using high-performance liquid chromatography (HPLC)-diode array detector (DAD)-mass spectrometry (MS); c CHO = Chinese hamster ovarian cell line; d selectivity index (SI) = (IC50 (CHO)/IC50 (PfNF54)). ND = not determined.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Vinindwa, B.; Dziwornu, G.A.; Masamba, W. Synthesis and Evaluation of Chalcone-Quinoline Based Molecular Hybrids as Potential Anti-Malarial Agents. Molecules 2021, 26, 4093. https://doi.org/10.3390/molecules26134093

AMA Style

Vinindwa B, Dziwornu GA, Masamba W. Synthesis and Evaluation of Chalcone-Quinoline Based Molecular Hybrids as Potential Anti-Malarial Agents. Molecules. 2021; 26(13):4093. https://doi.org/10.3390/molecules26134093

Chicago/Turabian Style

Vinindwa, Bonani, Godwin Akpeko Dziwornu, and Wayiza Masamba. 2021. "Synthesis and Evaluation of Chalcone-Quinoline Based Molecular Hybrids as Potential Anti-Malarial Agents" Molecules 26, no. 13: 4093. https://doi.org/10.3390/molecules26134093

APA Style

Vinindwa, B., Dziwornu, G. A., & Masamba, W. (2021). Synthesis and Evaluation of Chalcone-Quinoline Based Molecular Hybrids as Potential Anti-Malarial Agents. Molecules, 26(13), 4093. https://doi.org/10.3390/molecules26134093

Article Metrics

Back to TopTop